Insilico advances an AI-discovered IPF drug to Phase III

AI News reports that Insilico Medicine is advancing rentosertib, an AI-identified drug candidate for idiopathic pulmonary fibrosis, into Phase III trials. The article says a randomized 71-patient Phase IIa study across 22 Chinese clinical sites showed a mean forced vital capacity gain of 98.4 mL in the 60 mg daily arm, compared with a 20.3 mL loss for placebo. The program used Insilico's Pharma.AI platform, including PandaOmics for target discovery and Chemistry42 for generative molecular design.

Key details: Rentosertib is advancing to Phase III trials for idiopathic pulmonary fibrosis, The Phase IIa study involved 71 patients across 22 Chinese clinical sites, The 60 mg daily arm showed a mean forced vital capacity gain of 98.4 mL, Insilico says the program used PandaOmics and Chemistry42.

Why it matters: AI drug discovery needs clinical proof, and Phase III is where the field's strongest claims start facing real efficacy tests.